CART Peptide

II. What is this compound?

The story starts with a gene rather than a lab synthesis. CART is an endogenous neuropeptide — encoded by the *CARTPT* gene, produced by your own body, and so conserved across evolution that rodents and humans share roughly 95% amino acid identity [4] PMID: 25352770 . When a sequence barely changes over millions of years, evolution is flagging it: whatever this molecule does, it matters too much to break.

The naming gets technical quickly, so here's the map. The gene is transcribed into two alternatively spliced mRNAs — proCART 1–89 and proCART 1–102 — which post-translational processing then trims into the biologically active fragments CART (55–102) and CART (62–102) [5] PMID: 9924797 . The full-length prepro-CART protein runs 116 amino acids at approximately 12,829 Da.

Where does it operate? Concentrated in the brain regions that govern homeostatic regulation: the arcuate nucleus — the same hub that processes leptin signals — plus the paraventricular nucleus, lateral hypothalamic area, and nucleus accumbens [6] PMID: 25352770 . Peripheral outposts include the gastrointestinal tract's myenteric plexus, pancreatic islets, vagal afferents, and white adipose tissue.

Then comes the field's great unsolved puzzle: CART's receptor remains unidentified. Signaling clearly involves Gi/o protein-coupled pathways — pertussis toxin sensitivity gave that away — but the specific molecular target has resisted characterization [7] PMID: 25352770 . That single gap shapes everything downstream, from drug development strategy to how researchers actually study this peptide.

III. How it works

To picture what CART does, imagine the hypothalamic circuits the brain uses to balance a checkbook: energy in versus energy out. Research suggests its primary role runs through Gi/o protein-coupled receptors in the arcuate and paraventricular nuclei [8] PMID: 25352770 — though the receptor itself remains unidentified, a mystery worth carrying through this whole section.

The context that makes CART interesting is its position in the leptin story. CART is co-expressed with POMC/α-MSH neurons — the same population that carries leptin's "fat stores are adequate" message — and leptin positively regulates CART mRNA expression there [9] PMID: 16102267 . When leptin rises, CART production follows, placing CART downstream of adiposity sensing: one of the effector neuropeptides translating metabolic state into actual feeding behavior.

There's a gut-level dimension too. CART and cholecystokinin act synergistically to suppress feeding — CCK delivers short-term satiety signals from the gut while CART amplifies them centrally [10] PMID: 25352770 . Immediate meal signals and long-term energy status, integrated by a single circuit.

But here's the twist that keeps researchers honest: location changes everything. Central administration consistently inhibits feeding, yet direct injection into specific hypothalamic nuclei — arcuate, ventromedial, dorsomedial — can paradoxically stimulate food intake [11] PMID: 25352770 . CART apparently serves both appetite-braking and appetite-driving circuits, with the net result depending on which pathway predominates.

Finally, reward. In the nucleus accumbens, CART modulates dopaminergic pathways, attenuating the locomotor and reinforcing effects of psychostimulants [12] PMID: 33757831 . Appetite regulation plus reward modulation puts CART at the intersection of homeostatic and hedonic eating — exactly where modern obesity research is heading next.

• Anorexigenic signaling via Gi/o protein-coupled receptors in hypothalamic nuclei
  PMID 25352770PMID 9661247
• Positive regulation by leptin in the arcuate nucleus, linking CART to adiposity signaling
  PMID 25352770PMID 16102267
• Modulation of dopaminergic reward pathways in the nucleus accumbens
  PMID 25352770PMID 33757831
• Synergistic appetite suppression with cholecystokinin (CCK) in vagal afferent signaling
  PMID 25352770

IV. Research Findings

Start with the most reproducible finding in the field. When CART peptide fragments are administered centrally in rodent models, food intake drops consistently — demonstrated across multiple experimental paradigms and injection sites [13] PMID: 9661247 . In neuropeptide feeding research, where effects often wobble between labs, that repeatability is rare currency.

What happens without CART tells the complementary story. Knockout mice gain excess body weight versus wild-type littermates — especially on high-fat diets — with the gain driven primarily by fat mass, though some models also show reduced lean mass [14] PMID: 16102267 . One detail deserves a spotlight: these animals show a lower respiratory exchange ratio, meaning metabolism shifts toward burning fat over carbohydrate. CART appears to influence fuel selection, not merely caloric intake.

Zoom out and the framework snaps into focus: energy homeostasis. CART operates inside the leptin-melanocortin pathway as one of several effector neuropeptides converting hormonal signals about energy stores into behavioral and metabolic output [15] PMID: 25352770 — which explains its appeal to researchers modeling how the brain coordinates appetite, expenditure, and body composition as one system.

A separate thread runs through reward. In the nucleus accumbens, CART attenuates psychostimulant effects on dopaminergic signaling [16] PMID: 33757831 — relevant to food reward, the hedonic side of eating that operates independently of true hunger, and to addiction biology more broadly.

Where does the human evidence sit? Nowhere yet: every documented effect derives from preclinical animal studies and genetic models, with no clinical trials conducted. That boundary doesn't close the story — it defines the frontier this page has been mapping.

• appetite-suppression preclinical
  PMID 9661247PMID 25352770
• energy-homeostasis preclinical
  PMID 25352770PMID 33757831
• body-weight-regulation preclinical
  PMID 16102267PMID 16762453
• reward-pathway-modulation preclinical
  PMID 25352770

V. Dosage Context Explained

No human dosing data exists for CART — the peptide has never been administered to human subjects in controlled research. Every number below comes from animal work, and even those arrive with asterisks attached.

In rodent studies, the standard route is intracerebroventricular (i.c.v.) injection, with reported doses ranging from 0.1 to 2.0 micrograms per injection [17] PMID: 9661247 . Some experimental designs use intraperitoneal administration instead, but central delivery remains standard given CART's primary role as a neuropeptide acting within the CNS.

The deeper complication is directional. Without a characterized receptor — and given the site-specific paradox described earlier — dose-response relationships turn complex and context-dependent: what suppresses appetite in one brain region may stimulate it in another [18] PMID: 25352770 . Here, a dose isn't just a quantity; it's a quantity plus a destination.

That's why no established protocols, validated dosing guidelines, or standardized administration schedules exist for this peptide in any context. Each experiment becomes a design problem of its own — which naturally raises the question of what the safety landscape looks like.

• Administration Routes

  intracerebroventricular

  Range

  0.1–2.0 µg per injection in rodent models

  animal research only; no human dosing data exists

  PMID 9661247PMID 25352770

VI. Side Effects: Research Context

The honest answer arrives first: the human safety profile of CART is entirely unknown — no clinical trials, toxicity studies, or systematic safety assessments exist. What researchers do know comes from genetics rather than administration.

The most informative data comes from knockout studies. Mice lacking CART develop increased body weight and fat mass, particularly on high-fat diets [19] PMID: 16102267 — evidence that chronic CART *deficiency* promotes an obesogenic metabolic phenotype. The mirror-image question, what chronic excess does over time, hasn't been systematically characterized in either direction.

Site-specificity cuts both ways as well: since CART suppresses appetite in some brain regions while stimulating it in others [20] PMID: 25352770 , uncontrolled or non-targeted modulation could theoretically produce unpredictable effects on feeding behavior. And while no contraindications have been formally established, theoretical concerns cluster around eating disorders, severe metabolic dysregulation, and conditions involving hypothalamic dysfunction.

None of this amounts to demonstrated risk — it amounts to unmapped territory. How regulators treat compounds sitting in exactly that position, promising biology paired with zero clinical data, is the subject of the final section below.

• no human safety data available
• CART knockout mice show increased body weight and fat mass on high-fat diets (preclinical)
• site-specific paradoxical orexigenic effects observed with direct intranuclear injection in rodents

VII. Frequently Asked Questions